Medicine
Cibinqo 50 mg tablet
Cibinqo 50 mg tablet is a prescription medicine containing Abrocitinib for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store CIBINQO at 20°C to 25°C (68°F to 77°F), excursions permitted between…
Key facts
- Active ingredient (INN)
- Abrocitinib
- Brand
- Cibinqo
- Strength
- 50 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store CIBINQO at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D11AH08 Abrocitinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 February 2022
- Identifiers
- RxCUI 2591481, 2591487, 2591489 +3DailyMed set ID 3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258, 16c12a56-4550-414b-ac9d-b785b41fea6bNDC 0069-0235, 63539-236Application NDA213871
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 0069-0235-30 | Pfizer Laboratories | 24 February 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Abrocitinib
Clinical summary
Abrocitinib is a janus kinase inhibitor indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis, among other approved uses. MedsAcross supplies Abrocitinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AbrocitinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CIBINQO prescribing information (US Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Cibinqo: European public assessment report (EPAR) · European Medicines Agency
Need Cibinqo 50 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.